On January 10, 2025, 4D Molecular Therapeutics announced a strategic pipeline focus, prioritizing its highest-value programs: 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and 4D-710 for cystic fibrosis. This strategic pivot aims to optimize resource allocation and accelerate the development of these key product candidates.
The company confirmed that its 4FRONT-1 and 4FRONT-2 Phase 3 trials for 4D-150 in wet AMD are on track to initiate in the first quarter of 2025 and the third quarter of 2025, respectively. Topline 52-week data for both pivotal trials is expected in the second half of 2027, providing clear milestones for investors.
Furthermore, 4DMT announced an extended cash runway, with its capital now projected to fund planned operations into 2028. This extension provides financial stability and supports the company's ability to deliver critical clinical data without immediate financing needs, underscoring a disciplined approach to capital management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.